in addition , patients receiving vmcp-vbap ( +/- levamisole ) had a survival duration determined to be significantly increased by all forms of analysis : 48 and 33 months for vmcp-vbap without and with levamisole v 29 and 26 months for vcp without and with levamisole ( p = .011 overall ) .
C0078398
vmcp
C0032952
vcp